Uncategorized Archives - Page 107 of 112

TuesdayNov 21, 2017 10:15 am

Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) is “One to Watch”

Management, R&D team boasts decades of industry leadership Pipeline includes therapies targeting chronic pain, nausea, inflammation, muscle spasms, epilepsy and Post Traumatic Stress Disorder Unique result-driven strategy strongly positions Veritas in the medical marijuana industry Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) is an emerging pharmaceutical and IP development company publicly traded in Canada, the United States and Germany. Through its recently acquired 80 percent stake in Cannevert Therapeutics Ltd., also known as Veritas’ R&D arm, the company is clinically profiling various marijuana cultivars to pharmacologically connect unique strains with specific disease conditions. Veritas Pharma’s goal is to perform clinical…

MondayNov 13, 2017 3:34 pm

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Driving Cannabis Costs Down While Meeting Patient Needs

Strong cash position of over $40 million to fund aggressive expansion timeline One of first companies to obtain cannabis production license from Health Canada Infrastructure in place to take advantage of projected $9 billion Canadian cannabis market Sees ample opportunities in Western Europe with first marketing push in Germany Abcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF), a manufacturer and distributor of medical cannabis in Canada, is creating a consistent, organically grown, pesticide-free standardized product that is keeping costs down and investors excited. Abcann’s approach to growing cannabis centers on replicating the natural environment of any geographical location for a product…

WednesdayNov 08, 2017 2:41 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Boosts Revenue by Out-Licensing Patented Technology to Third-Party Partners

High-margin licensing royalties of 5-10% of gross sales of its patented bioscience technology and process are an attractive valuation builder; LXRP sees more licensing opportunities in 2018 LXRP’s technology is patented in the U.S. and Australia; company has national/regional filings pending in 44 countries Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) generates revenue by out-licensing its patented global technology related to ingestion of edible cannabinoids at a rate of 5-10% of gross sales to its third-party partners. LXRP has also expanded its process of improved and faster inhalation by the body of fat-soluble vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) in pain…

TuesdayNov 07, 2017 11:05 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Supplements Popular Beverage with Legal CBD

Unique patented drug delivery platform Active in world’s largest beverage market Technology that compliments rather than competes with CBD companies An old and popular beverage is being supplemented in a healthy, flavorful way now that Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is on the scene. Having increased its ownership stake in PoViva Tea, LLC from 51% to 100%, the innovative drug delivery biotech plans to apply its patented DehydraTECH™ technology to supplement a range of black teas with cannabidiol (CBD) from hemp. After water, tea is the most widely consumed beverage in the world and is an ideal adjuvant…

WednesdayOct 25, 2017 2:54 pm

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Seeks to Become A ‘Global Presence’

Sees opportunities for legalized marijuana marketing in Canada, Germany, all of Western Europe and South America Armed with $43 million in working capital, it sees advantages for itself in product and financing It has a proprietary process in its indoor growing environment to control temperature, humidity and water to produce standardized, pesticide-free cannabis ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) director Aaron Keay said in an interview with CannabisFN (CFN Media) that besides achieving greater market share in Canada, ABcann Global also sees opportunities for growth and presence in Western Europe, Germany and South America (http://cnw.fm/SvJr1). The company sells in…

MondayOct 23, 2017 3:41 pm

Liberty Leaf Holdings Ltd. (OTCQB: LIBFF) (CSE: LIB) (FSE: HN3P) Subsidiary Plans to Boost Storage Capacity

In new business plan sent to Health Canada, subsidiary North Road Ventures proposes doubling its cannabis product lines, adding oil products (CBD) and boosting by five-fold its storage capacity Statista report projects Canadian marijuana market will reach C$2.8 billion by 2020 Company sees cannabis oil products accounting for 50% or more of projected sales Liberty Leaf Holdings Ltd.’s (OTCQB: LIBFF) (CSE: LIB) (FSE: HN3P) wholly own subsidiary, North Road Ventures, has abridged its application to Health Canada, detailing its plans to double its cannabis product lines, adding cannabis oil products (CBD), and boost by five-fold its vault storage capacity to…

FridayOct 20, 2017 9:19 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) to Hold Web-Meeting on November 1

Web-meeting scheduled for November 1, 2017, at 4:15 p.m. ET 19 patents filed encompassing 44 countries Patents cover broad range of lipophilic bio-actives including cannabinoids, vitamins and other pharma Patented lipophilic delivery system proven to improve bio-absorption The medical effectiveness of cannabinoids is no longer in question, and the cannabinoid market proliferates ever faster as more people realize the therapeutic benefits. However, the human gastrointestinal tract just doesn’t absorb cannabinoids effectively, and much of what is ingested is subsequently excreted by the body, causing onset times and efficacy to vary wildly. With 19 patent applications filed internationally covering 44 countries,…

ThursdayOct 19, 2017 12:52 pm

InMed Pharmaceuticals, Inc.’s (CSE: IN) (OTCQB: IMLFF) Biosynthesis Technology Demonstrates Robust Diversity

Biosynthesis technology making strong advances Two promising pipeline candidates Inclusion in the CSE25 Index InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) continues down the fast track with its proprietary technology for the microbial biosynthesis of cannabinoids (http://cnw.fm/uIL78). The company recently announced it has enabled the production of all four "gateway" cannabinoids using genetically engineered microorganisms. From these gateway substrates, production of all 90+ cannabinoids is possible via biosynthesis. InMed’s breakthrough stands to make the production of cannabis derivatives, including THC, CBD and trace cannabinoids, a much more commercially feasible proposition. The Company currently has two lead drug candidates that employ…

ThursdayOct 12, 2017 9:30 am

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) Oral Digestion Technology Needs No Sugar Coating

Delivery technology with application to all non-psychoactive cannabinoids Company is an enabler rather than competitor to hemp oil producers Revenue from licensing DehydraTECH oral digestion technology Thanks to Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), there’s no need for a spoonful of sugar to help the medicine go down. This innovative biotech has developed technology that masks the strong taste and odor of hemp oil products, eschewing the need for artificial sweeteners, which tend to come with their own fallout to heart and health. Lexaria’s DehydraTECH oral digestion technology is a ‘back office’ process that solves the taste and odor…

TuesdayOct 10, 2017 12:53 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Bioabsorption Tech Boosting Development of CBD Products

Technology improves absorption of cannabidiol and bioactive compounds into the bloodstream It is now being used on all non-psychoactive cannabinoids and applied to edibles and health food products Patents have been awarded in the U.S. and Australia and are pending in 44 countries Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds. Its patent-protected technology has improved the ability of cannabinoid-products companies to deliver active ingredients to the body. With patents pending for tetrahydrocannabinol and other psychoactive cannabinoids (plus nicotine and non-steroidal anti-inflammatory drugs), the current technology…

News and Publishing Service for Cannabis Related, Canadian Companies

Contact us: 512.354.7000

Category: Uncategorized